RENO-DIP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RENO-DIP (RENO-DIP).
RENO-DIP (dipyridamole) is a platelet aggregation inhibitor that inhibits adenosine deaminase and phosphodiesterase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and blocks adenosine reuptake, resulting in vasodilation and inhibition of platelet aggregation.
| Metabolism | Metabolized primarily by the liver via glucuronidation; forms a monoglucuronide conjugate. Excreted mainly in bile as glucuronide conjugates. |
| Excretion | Primarily renal excretion of unchanged drug (70%) via glomerular filtration and active tubular secretion; 20% excreted as metabolites in urine; 10% eliminated in feces via biliary secretion. |
| Half-life | Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound to serum albumin; minimal binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2 L/kg (approximately 14 L in a 70 kg adult), indicating distribution primarily in extracellular fluid; increased in edema states. |
| Bioavailability | Oral: 65-80% (average 72%) with interindividual variability; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | 6-12 hours for diuretic effect; may persist up to 24 hours in renal impairment due to reduced clearance. |
Hypertension: initial 10 mg orally once daily, titrate to 40 mg once daily. Heart failure: initial 2.5 mg orally twice daily, titrate to 20 mg twice daily as tolerated.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30-60 mL/min: reduce dose by 50%. eGFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Not recommended for children <18 years due to lack of safety and efficacy data. |
| Geriatric use | Start at lowest dose (2.5 mg twice daily) and titrate slowly; monitor renal function and electrolytes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RENO-DIP (RENO-DIP).
| Breastfeeding | Dipyridamole and aspirin (components) are excreted in breast milk in low amounts. M/P ratio for dipyridamole approximately 0.3; aspirin M/P ratio ~0.6. No known adverse effects in nursing infants at therapeutic doses. Caution with high-dose aspirin due to risk of Reye's syndrome. Generally compatible with breastfeeding. |
| Teratogenic Risk | First trimester: Dipyridamole (component) - limited human data, animal studies show no teratogenicity; low risk. Second and third trimesters: May cause uterine relaxation and potential for maternal hypotension; theoretical risk of fetal hypoxia due to maternal hypotension. Overall, considered low teratogenic risk but use only if clearly needed. |
■ FDA Black Box Warning
Intravenous dipyridamole can cause serious adverse reactions including myocardial infarction, cardiac arrest, ventricular arrhythmias, and cerebrovascular events (e.g., stroke, transient ischemic attack). Resuscitation equipment and trained personnel must be available. Avoid in patients with unstable angina, acute myocardial infarction, or critical aortic stenosis.
| Serious Effects |
Hypersensitivity to dipyridamole or any component; unstable angina; acute myocardial infarction (within 48 hours); critical aortic stenosis; patients with known or suspected bronchospastic lung disease (relative).
| Precautions | May cause bronchospasm in patients with COPD or asthma; use with caution and have bronchodilators available. Risk of hypotension; ensure patient is well-hydrated. May precipitate angina or myocardial ischemia. Use with caution in patients with left ventricular outflow obstruction. Elderly patients may be more sensitive to hemodynamic effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of bleeding. Assess fetal heart rate and uterine activity if used near term. Periodic monitoring of renal function and platelet count. Evaluate for evidence of placental abruption or hemorrhage. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at therapeutic doses. Aspirin may inhibit ovulation at high doses but not at low doses used in RENO-DIP. |